Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05403801 · ClinicalTrials.gov registry record · NA
STAMP+CBT mHealth for Cancer Pain
A NA study of Advanced Cancer and Palliative Care, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT05403801: Completed NA study of Advanced Cancer and Palliative Care, sponsored by Dana-Farber Cancer Institute.
NCT05403801 is a NA study of Advanced Cancer and Palliative Care that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05403801, a NA study of Advanced Cancer and Palliative Care, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to test whether a mobile application developed to help people with cancer pain is useful and helpful to patients with cancer.
Primary Outcome
\>70% of subjects complete \>4 of the 6 pain-CBT modules and patients will complete 50% of surveys by the end of 4 weeks (completion of the 4-week intervention study period)
Conditions Studied
Interventions
- BEHAVIORAL STAMP+CBT application
Study Locations (3)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Dana-Farber at Merrimack Valley - Methuen
New Hampshire
- Dana-Farber at Londonderry - Londonderry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2023-06-27 |
| Phase | NA |
What the finished NCT05403801 record still lists
NCT05403801 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (96% lower).
The record links to 5 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which STAMP+CBT application is the first listed.
NCT05403801 reports a single indexed study location in Massachusetts, New Hampshire.
Frequently Asked Questions
What is clinical trial NCT05403801 about?
NCT05403801 is a clinical study titled "STAMP+CBT mHealth for Cancer Pain". The purpose of this study is to test whether a mobile application developed to help people with cancer pain is useful and helpful to patients with cancer.
What is the current status of trial NCT05403801?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2022-07-01. Estimated completion is 2023-06-27.
What conditions does trial NCT05403801 study?
This clinical trial studies the following conditions: Advanced Cancer, Palliative Care, Active Cancer, Active Cancer Treatment, Chronic Pain Due to Cancer.
What interventions are being tested in trial NCT05403801?
The interventions under investigation include: STAMP+CBT application (BEHAVIORAL).
Who is sponsoring clinical trial NCT05403801?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05403801 being conducted?
This trial has 3 study locations across Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05403801's enrollment target sits among peer trials
10 119th of 122 higher than 3 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
RECRUITING · NA
-
Pilot Trial of Spiritual Care Interventions for Patients With Cancer
RECRUITING · NA
-
Electronic Patient Reporting of Symptoms and Unmet Needs to Connect Patients With Advanced Cancer to Palliative Care Services
RECRUITING · NA
-
ALIGN for Older Adults With Cancer in SNFs
RECRUITING · NA
-
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI